MIAMI, FLORIDA / ACCESS Newswire / April 1, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing ...

BlackRock's recently posted CEO Larry Fink’s 2025 Annual Chairman’s Letter to Investors. Click here to read the full fund ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

GLP-1 users are upping their purchases of frozen fruits (44%) and vegetables (40%) while reducing impulse purchases and larger meal portions. 80% of GLP-1 users expressed interest in trying frozen ...

Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief ...